VivoSim Labs, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VIVS research report →
About the company
VivoSim Labs, Inc. , a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models.
- CEO
- Keith Murphy
- IPO
- 2012
- Employees
- 14
- HQ
- San Diego, CA, US
Price Chart
- Market Cap
- $2.56M
- P/E
- -1.17
- P/S
- 18.00
- P/B
- 0.32
- EV/EBITDA
- 1.18
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -8066.20%
- Net Margin
- -864.08%
- ROE
- -15.56%
- ROIC
- -228.26%
- Revenue
- $144.00K · 32.11%
- Net Income
- $-2,488,000 · 83.04%
- EPS
- $-1.70 · 91.17%
- Op Income
- $-12,616,000
- FCF YoY
- 35.53%
- 52W High
- $5.30
- 52W Low
- $0.95
- 50D MA
- $1.27
- 200D MA
- $1.98
- Beta
- 1.40
- Avg Volume
- 70.28K
Get TickerSpark's AI analysis on VIVS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 27, 26 | Cohen Douglas Jay | other | 15,000 |
| Jan 27, 26 | Murphy Keith | other | 15,000 |
| Jan 27, 26 | Milhous Alison Tjosvold | other | 15,000 |
| Jan 27, 26 | Gobel David | other | 15,000 |
| Jan 27, 26 | STERN ADAM K | other | 15,000 |
| Nov 25, 25 | Sethi Amar Akhtar | other | 53,500 |
| Nov 24, 25 | Sethi Amar Akhtar | other | 0 |
| Nov 17, 25 | Gobel David | sell | 3,266 |
| Aug 11, 25 | Lialin Tony Serge | other | 40,000 |
| Aug 11, 25 | Lialin Tony Serge | other | 0 |
Our VIVS coverage
Recent articles, reports, and earnings notes.
No research on VIVS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VIVS report →Similar companies
Peers in the same neighborhood.